Previous 10 | Next 10 |
Cancer treatment is one of the hottest areas of healthcare investing these days, with personalized medicine like genetic therapies providing new promises of treatment and potential cures. Still, despite the progress that researchers have made, there are still plenty of false starts and treatme...
As for literary criticism in general: I have long felt that any reviewer who expresses rage and loathing for a novel or a play or a poem is preposterous. He or she is like a person who has put on full armor and attacked a hot fudge sundae or a banana split .” - Kurt Vonnegut Over t...
Exelixis, Inc. (NASDAQ:EXEL) Q2 2019 Earnings Conference Call July 31, 2019 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President-Public Affairs and Investor Relations Mike Morrissey - President and Chief Executive Officer Chris Senner - Chief Financial Offic...
The following slide deck was published by Exelixis, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Exelixis (NASDAQ: EXEL ): Q2 Non-GAAP EPS of $0.29; GAAP EPS of $0.25 beats by $0.02 . Revenue of $240.3M (+29.1% Y/Y) beats by $13.33M . Shares +0.7% . Press Release More news on: Exelixis, Inc., Earnings news and commentary, Healthcare stocks news,
- Total Revenue of $240.3 Million, Cabozantinib Franchise Revenue of $193.7 Million - - GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.29 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today reported financia...
– Companies will partner to advance small molecules in up to six discrete projects, including three existing programs against specific predetermined targets – Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive collaboration, option and l...
Today, we want to share our analysis of Exelixis (EXEL) with you. The company's stock price has declined by more than 9% since mid-July despite the absence of company-specific negative news . The company has a debt-free balance sheet, strong pipeline progress, and its lead drug continues to g...
Note: This article was first revealed to subscribers to my exclusive marketplace, The Formula , in February when shares of Blueprint were trading < $80. Preface Documents: 10-Q | Company Slides Shares: 48,853,933 | PPS: $100 | Market Cap: $4.8B | Enterprise Value...
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2019 financial results will be released on Wednesday, July 31, 2019 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...